Blood Cancer Journal - Table of Contents alert Volume 7 February 2017

If you are unable to see the message below, click here to view.

Advertisement Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders. Explore the benefits of submitting your next research article. TABLE OF CONTENTS Volume 7, February 2017 In this issue Reviews Original Articles Letters to the Editor Sign up for e-alerts Web feed Reviews Top Acute myeloid leukemia targets for bispecific antibodies S S Hoseini and N K Cheung Blood Cancer J 2017 7: e522; 10.1038/bcj.2017.2 Abstract | Full Text The role of the extracellular matrix in primary myelofibrosis O Leiva, S K Ng, S Chitalia, A Balduini, S Matsuura and K Ravid Blood Cancer J 2017 7: e525; 10.1038/bcj.2017.6 Abstract | Full Text Germline mutations predisposing to diffuse large B-cell lymphoma O C Leeksma, N F de Miranda and H Veelken Blood Cancer J 2017 7: e532; 10.1038/bcj.2017.15 Abstract | Full Text Original Articles Top A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens I Baccelli, J Krosl, G Boucher, I Boivin, V-P Lavallée, J Hébert, S Lemieux, A Marinier and G Sauvageau Blood Cancer J 2017 7: e529; 10.1038/bcj.2017.10 Abstract | Full Text Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker S S Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, C K Stein, O Stephens, N Weinhold, N Petty, D Steward, L Rasche, M Bauer, C Ashby, E Peterson, S Ali, J Ross, V A Miller, P Stephens, S Thanendrarajan, C Schinke, M Zangari, F van Rhee, B Barlogie, T I Mughal, F E Davies, G J Morgan and B A Walker Blood Cancer J 2017 7: e535; 10.1038/bcj.2017.12 Abstract | Full Text The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells Y Nishida, A Maeda, M J Kim, L Cao, Y Kubota, J Ishizawa, A AlRawi, Y Kato, A Iwama, M Fujisawa, K Matsue, M Weetall, M Dumble, M Andreeff, T W Davis, A Branstrom, S Kimura and K Kojima Blood Cancer J 2017 7: e527; 10.1038/bcj.2017.8 Abstract | Full Text Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies E C Pietsch, J Dong, R Cardoso, X Zhang, D Chin, R Hawkins, T Dinh, M Zhou, B Strake, P-H Feng, M Rocca, C Dos Santos, X Shan, G Danet-Desnoyers, F Shi, E Kaiser, H J Millar, S Fenton, R Swanson, J A Nemeth and R M Attar Blood Cancer J 2017 7: e536; 10.1038/bcj.2017.7 Abstract | Full Text Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia P Richter-Pechańska, J B Kunz, J Hof, M Zimmermann, T Rausch, O R Bandapalli, E Orlova, G Scapinello, J C Sagi, M Stanulla, M Schrappe, G Cario, R Kirschner-Schwabe, C Eckert, V Benes, J O Korbel, M U Muckenthaler and A E Kulozik Blood Cancer J 2017 7: e523; 10.1038/bcj.2017.3 Abstract | Full Text Mutational landscape reflects the biological continuum of plasma cell dyscrasias A Rossi, M Voigtlaender, S Janjetovic, B Thiele, M Alawi, M März, A Brandt, T Hansen, J Radloff, G Schön, U Hegenbart, S Schönland, C Langer, C Bokemeyer and M Binder Blood Cancer J 2017 7: e537; 10.1038/bcj.2017.19 Abstract | Full Text Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma N Tandon, S V Rajkumar, B LaPlant, A Pettinger, M Q Lacy, A Dispenzieri, F K Buadi, M A Gertz, S R Hayman, N Leung, R S Go, D Dingli, P Kapoor, Y Lin, Y L Hwa, A L Fonder, M A Hobbs, S R Zeldenrust, J A Lust, W I Gonsalves, S J Russell and S K Kumar Blood Cancer J 2017 7: e528; 10.1038/bcj.2017.13 Abstract | Full Text Letters to the Editor Top Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia Z Chen, L J Medeiros, H M Kantajian, L Zheng, Z Gong, K P Patel, H Xiong, W Wang, J E Cortes and S Hu Blood Cancer J 2017 7: e521; 10.1038/bcj.2017.4 Full Text Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma N Lee, S Y Moon, J-h Lee, H-K Park, S-Y Kong, S-M Bang, J H Lee, S-S Yoon and D S Lee Blood Cancer J 2017 7: e530; 10.1038/bcj.2017.14 Full Text Splenectomy as a diagnostic method in lymphoma-associated hemophagocytic lymphohistiocytosis of unknown origin J Ma, Z Jiang, T Ding, H Xu, J Song, J Zhang, Y Xie and W Wang Blood Cancer J 2017 7: e534; 10.1038/bcj.2016.125 Full Text Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study M Montillo, S O'Brien, A Tedeschi, J C Byrd, C Dearden, D Gill, J R Brown, J C Barrientos, S P Mulligan, R R Furman, F Cymbalista, C Plascencia, S Chang, E Hsu, D F James and P Hillmen Blood Cancer J 2017 7: e524; 10.1038/bcj.2017.5 Full Text Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia J G Sfeir, M T Drake, B R LaPlant, M J Maurer, B K Link, T J Berndt, T D Shanafelt, J R Cerhan, T M Habermann, A L Feldman and T Witzig Blood Cancer J 2017 7: e526; 10.1038/bcj.2017.9 Full Text Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes R T Swords, J Watts, H P Erba, J K Altman, M Maris, F Anwer, Z Hua, H Stein, H Faessel, F Sedarati, B J Dezube, F J Giles, B C Medeiros and D J DeAngelo Blood Cancer J 2017 7: e520; 10.1038/bcj.2017.1 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.